Gujarat Alkalies & Chemicals Ltd
- Market Cap ₹ 3,453 Cr.
- Current Price ₹ 470
- High / Low ₹ 700 / 418
- Stock P/E
- Book Value ₹ 759
- Dividend Yield 3.36 %
- ROCE -0.34 %
- ROE -1.13 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.62 times its book value
- Stock is providing a good dividend yield of 3.36%.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 8.37% over past five years.
- Company has a low return on equity of 0.59% over last 3 years.
- Earnings include an other income of Rs.123 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Part of BSE Allcap BSE Commodities
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,995 | 2,070 | 2,455 | 3,161 | 2,725 | 2,429 | 3,759 | 4,516 | 3,807 | 4,073 | 4,308 | |
| 1,660 | 1,622 | 1,669 | 2,046 | 2,148 | 2,072 | 2,774 | 3,568 | 3,775 | 3,793 | 3,942 | |
| Operating Profit | 335 | 448 | 786 | 1,115 | 577 | 357 | 984 | 949 | 32 | 279 | 366 |
| OPM % | 17% | 22% | 32% | 35% | 21% | 15% | 26% | 21% | 1% | 7% | 8% |
| 45 | 56 | 106 | 62 | 90 | 67 | 46 | 42 | 90 | 92 | 123 | |
| Interest | 10 | 13 | 15 | 21 | 14 | 15 | 6 | 19 | 45 | 51 | 66 |
| Depreciation | 107 | 111 | 127 | 140 | 162 | 174 | 198 | 276 | 377 | 392 | 407 |
| Profit before tax | 262 | 381 | 749 | 1,016 | 491 | 235 | 826 | 695 | -300 | -71 | 16 |
| Tax % | 16% | 19% | 29% | 32% | 32% | 29% | 32% | 41% | -21% | -9% | |
| 220 | 307 | 534 | 690 | 332 | 166 | 560 | 410 | -237 | -65 | -9 | |
| EPS in Rs | 29.90 | 41.85 | 72.78 | 93.98 | 45.22 | 22.57 | 76.22 | 55.78 | -32.25 | -8.87 | -1.17 |
| Dividend Payout % | 15% | 12% | 9% | 9% | 18% | 35% | 13% | 42% | -43% | -178% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 3% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 93% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 6% |
| 3 Years: | -10% |
| 1 Year: | -8% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 3% |
| 3 Years: | 1% |
| Last Year: | -1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 |
| Reserves | 2,854 | 3,282 | 3,748 | 4,222 | 4,522 | 5,301 | 5,826 | 6,066 | 6,002 | 5,596 | 5,497 |
| 295 | 353 | 291 | 247 | 205 | 498 | 594 | 597 | 544 | 561 | 637 | |
| 671 | 726 | 859 | 988 | 1,090 | 1,282 | 1,484 | 1,599 | 1,404 | 1,756 | 2,002 | |
| Total Liabilities | 3,894 | 4,435 | 4,970 | 5,531 | 5,891 | 7,154 | 7,977 | 8,335 | 8,023 | 7,987 | 8,209 |
| 1,821 | 2,073 | 2,104 | 2,300 | 2,610 | 2,587 | 2,702 | 4,250 | 4,617 | 4,584 | 4,522 | |
| CWIP | 83 | 151 | 252 | 307 | 445 | 1,109 | 1,787 | 544 | 95 | 79 | 37 |
| Investments | 854 | 1,016 | 1,145 | 1,065 | 1,242 | 2,092 | 2,110 | 1,831 | 2,093 | 1,976 | 2,044 |
| 1,136 | 1,196 | 1,469 | 1,858 | 1,594 | 1,366 | 1,379 | 1,710 | 1,218 | 1,348 | 1,607 | |
| Total Assets | 3,894 | 4,435 | 4,970 | 5,531 | 5,891 | 7,154 | 7,977 | 8,335 | 8,023 | 7,987 | 8,209 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 201 | 502 | 514 | 838 | 630 | 421 | 735 | 960 | 67 | 381 | |
| -352 | -467 | -395 | -581 | -634 | -334 | -804 | -662 | -90 | -264 | |
| 84 | 13 | -116 | -136 | -146 | 226 | 12 | -140 | -277 | -145 | |
| Net Cash Flow | -67 | 49 | 3 | 122 | -150 | 313 | -58 | 158 | -301 | -28 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 58 | 60 | 56 | 50 | 43 | 29 | 23 | 17 | 24 |
| Inventory Days | 99 | 94 | 147 | 99 | 92 | 88 | 101 | 111 | 93 | 110 |
| Days Payable | 99 | 125 | 154 | 134 | 126 | 111 | 101 | 119 | 86 | 115 |
| Cash Conversion Cycle | 60 | 27 | 53 | 22 | 17 | 21 | 29 | 15 | 25 | 19 |
| Working Capital Days | 89 | 81 | 98 | 96 | 107 | 10 | 4 | 5 | -1 | -3 |
| ROCE % | 11% | 18% | 24% | 11% | 5% | 13% | 11% | -4% | -0% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Production Volume: Caustic Soda (Lye) MT ・Standalone data |
|
|||||||||||
| Production Volume: Chloromethanes MT ・Standalone data |
||||||||||||
| Total Installed Capacity: Caustic Soda MTPA |
||||||||||||
| Installed Renewable Energy Capacity MW ・Standalone data |
||||||||||||
| Total Installed Capacity: Chloromethanes MTPA ・Standalone data |
||||||||||||
| Capacity Utilization: Caustic Soda Group % |
||||||||||||
| Domestic Market Share: Caustic Soda % ・Standalone data |
||||||||||||
| ECU Realization Rs/MT |
||||||||||||
| Average Cost of Power Consumed Rs/unit ・Standalone data |
||||||||||||
Documents
Announcements
-
Newspaper Advertisements
25 Feb - Special window from 05 Feb 2026 to 04 Feb 2027 for transfer/demat of physical securities per SEBI circular.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
24 Feb - Investors Presentation on Company''s website for the benefit of Investors/Shareholders at large. For more details kindly refer attached file.
- Newspaper Clippings Of The Postal Ballot Notice 19 Feb
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
18 Feb - Postal ballot to appoint Sanjay Joshi as independent director (Jan 1, 2026–Dec 31, 2030); voting Feb 20–Mar 21, 2026.
-
Inauguration Of Hydrogen Supply Pipeline To NOCIL Limited (NOCIL) At Dahej.
13 Feb - GACL inaugurated pipeline to NOCIL supplying ~20,000 Nm³/day; 5-year contract, ~Rs.9 Crore annual revenue.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
Concalls
-
Feb 2025TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
Mar 2024TranscriptAI SummaryPPT
-
Dec 2023TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
Jun 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Aug 2021TranscriptAI SummaryPPT
-
May 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Dec 2020TranscriptAI SummaryPPT
-
Aug 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Jun 2019TranscriptAI SummaryPPT
-
Mar 2017TranscriptAI SummaryPPT
-
May 2016TranscriptPPT
Product Offerings
The company has over 36 products in its portfolio, including Caustic Soda lye, flakes, and prills, Chloromethanes, Liquid Chlorine, Hydrochloric Acid, Hydrogen Peroxide, Anhydrous Aluminum Chloride, Caustic Potash lye and flakes, Potassium Carbonate granules and powder, Aluminium Chloride, Phosphoric Acid, etc. These products are utilized across industries such as textiles, pulp and paper, alumina, soaps& detergents, and water treatment, etc. [1]